

are found in tropical Africa and southern and southeast Asia, that exhibit effective antimalarial properties and offer important new weapons in the treatment of this devastating disease. The deadliest malarial parasites have become resistant to previously effective antimalarial drugs; therefore, effective new antimalarial drugs are urgently needed. These new naphthylisoquinoline compounds effectively inhibit the growth, reproduction, and pathologic effects of a broad spectrum of *Plasmodia* parasites, including drug-resistant strains.

Dated: October 13, 1998.

**Jack Spiegel,**

*Director, Division of Technology Development and Transfer, Office of Technology Transfer.*

[FR Doc. 98-27960 Filed 10-16-98; 8:45 am]

BILLING CODE 4140-01-M

**DEPARTMENT OF HEALTH AND HUMAN SERVICES**

**National Institutes of Health**

**National Cancer Institute; Notice of Closed Meetings**

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following meetings.

The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets of commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

*Name of Committee:* National Cancer Institute Special Emphasis Panel, Health Communications in Cancer Control.

*Date:* November 4-6, 1998.

*Time:* 7:00 pm to 5:00 pm.

*Agenda:* To review and evaluate grant applications.

*Place:* Gaithersburg Hilton, Gaithersburg, MD 20878.

*Contact Person:* C.M. Kerwin, PhD, Scientific Review Administrator, Special Review, Referral and Resources Branch, Division of Extramural Activities, National Cancer Institute, National Institutes of Health, 6130 Executive Boulevard/EPN-609, Rockville, MD 20892-7405, 301/496-7421.

*Name of Committee:* National Cancer Institute Special Emphasis Panel, Regional Variation in Breast Cancer Rates in the United States.

*Date:* November 9, 1998.

*Time:* 9:00 am to 5:00 pm.

*Agenda:* To review and evaluate grant applications.

*Place:* Executive Plaza North-Conference Room D, 6130 Executive Boulevard, Rockville, MD 20852.

*Contact Person:* Lalita D Palekar, Scientific Review Administrator, Special Review, Referral and Resources Branch, Division of Extramural Activities, National Cancer Institute, National Institutes of Health, 6130 Executive Boulevard/EPN-622B, Rockville, MD 20892-7405, 301/496-7575.

(Catalogue of Federal Domestic Assistance Program Nos. 93.392, Cancer Construction; 93.393, Cancer Cause and Prevention Research; 93.394, Cancer Detection and Diagnosis Research; 93.395, Cancer Treatment Research; 93.396, Cancer Biology Research; 93.397, Cancer Centers Support; 93.398, Cancer Research Manpower; 93.399, Cancer Control, National Institutes of Health, HHS)

Dated: October 13, 1998.

**LaVerne Y. Stringfield,**

*Committee Management Officer, NIH.*

[FR Doc. 98-27950 Filed 10-16-98; 8:45 am]

BILLING CODE 4140-01-M

**DEPARTMENT OF HEALTH AND HUMAN SERVICES**

**National Institutes of Health**

**National Cancer Institute; Notice of Closed Meeting**

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

*Name of Committee:* National Cancer Institute Special Emphasis Panel, Oncogenes in Cancer Etiology and Progression.

*Date:* November 4-5, 1998.

*Time:* 8:00 am to 5:00 pm.

*Agenda:* To review and evaluate grant applications.

*Place:* Crown Plaza Philadelphia Center City, 1800 Market Street, Philadelphia, PA 19103.

*Contact Person:* David Irwin, PhD, Research Programs Review Section Chief, Grants Review Branch, Division of Extramural Activities, National Cancer Institute, National Institutes of Health, 6130 Executive Boulevard, EPN-Room 635E, MSC 7405, Rockville, MD 20892-7405, (301) 402-0371, di4knih.gov.

(Catalogue of Federal Domestic Assistance Program Nos. 93.392, Cancer Construction; 93.393, Cancer Cause and Prevention Research; 93.394, Cancer Detection and Diagnosis Research; 93.395, Cancer Treatment Research; 93.396, Cancer Biology Research; 93.397, Cancer Centers Support; 93.398, Cancer Research Manpower; 93.399, Cancer Control, National Institutes of Health, HHS)

Dated: October 13, 1998.

**LaVerne Y. Stringfield,**

*Committee Management Officer, NIH.*

[FR Doc. 98-27951 Filed 10-16-98; 8:45 am]

BILLING CODE 4140-01-M

**DEPARTMENT OF HEALTH AND HUMAN SERVICES**

**National Institutes of Health**

**National Cancer Institute; Notice of Closed Meeting**

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of a meeting of the Board of Scientific Counselors, National Cancer Institute.

The meeting will be closed to the public as indicated below in accordance with the provisions set forth in section 552b(c)(6), Title 5 U.S.C., as amended for the review, discussion, and evaluation of individual intramural programs and projects conducted by the National Cancer Institute, including consideration of personnel qualifications and performance, and the competence of individual investigators, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

*Name of Committee:* Board of Scientific Counselors, National Cancer Institute, Subcommittee B—Basic Sciences.

*Date:* November 1-2, 1998.

*Time:* November 1, 1998, 7:00 pm to 10:30 pm.

*Agenda:* To review and evaluate administrative confidential matters.

*Place:* DoubleTree Hotel, 1750 Rockville Pike, Rockville, MD 20852.

*Time:* November 2, 1998, 8:00 am to 5:30 pm.

*Agenda:* To review and evaluate administrative confidential matters.

*Place:* National Cancer Institute, 9000 Rockville Pike, Building 31, C Wing, 6th Floor, Conference Room 10, Bethesda, MD 20892.

*Contact Person:* Florence E. Farber, PhD, Executive Secretary, Office of Advisory Activities, Division of Extramural Activities, National Cancer Institute, National Institutes of Health, 6130 Executive Boulevard, EPN 609, Rockville, MD 20892, 301/496-2378.

(Catalogue of Federal Domestic Assistance Program Nos. 93.392, Cancer Construction; 93.393, Cancer Cause and Prevention